^
    18d
    Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp (clinicaltrials.gov)
    P3, N=165, Recruiting, Biofrontera Bioscience GmbH | Trial completion date: Mar 2026 --> Jun 2026
    Trial completion date
    |
    Ameluz (aminolevulinic acid)
    3ms
    Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) (clinicaltrials.gov)
    P2, N=20, Recruiting, The Center for Clinical and Cosmetic Research
    New P2 trial
    |
    Ameluz (aminolevulinic acid)
    3ms
    Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Case Comprehensive Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Ameluz (aminolevulinic acid)
    4ms
    Duration of Ameluz Application in Acral Actinic Keratoses Response (clinicaltrials.gov)
    P4, N=28, Terminated, Royal Cornwall Hospitals Trust | Dr Xie abroad on other research, current PI Dr John Frewen not at main centre, no other available PI identified. Study suspended.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Ameluz (aminolevulinic acid)
    5ms
    Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp (clinicaltrials.gov)
    P3, N=165, Recruiting, Biofrontera Bioscience GmbH | Trial completion date: Apr 2025 --> Mar 2026 | Trial primary completion date: Jul 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    Ameluz (aminolevulinic acid)
    9ms
    Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). (clinicaltrials.gov)
    P3, N=186, Active, not recruiting, Biofrontera Bioscience GmbH | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial primary completion date
    |
    Ameluz (aminolevulinic acid)
    9ms
    Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults (clinicaltrials.gov)
    P2, N=126, Recruiting, Biofrontera Bioscience GmbH | Trial completion date: Mar 2024 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    Ameluz (aminolevulinic acid)
    10ms
    Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp (clinicaltrials.gov)
    P3, N=165, Recruiting, Biofrontera Bioscience GmbH | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Ameluz (aminolevulinic acid)
    12ms
    Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses (clinicaltrials.gov)
    P2, N=30, Recruiting, Case Comprehensive Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Oct 2023
    Enrollment open • Trial initiation date
    |
    Ameluz (aminolevulinic acid)
    1year
    Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Case Comprehensive Cancer Center | Initiation date: Sep 2023 --> Mar 2024
    Trial initiation date
    |
    Ameluz (aminolevulinic acid)